| Symbol | EXEL |
|---|---|
| Name | EXELIXIS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 1851 HARBOR BAY PARKWAY, ALAMEDA, California, 94502, United States |
| Telephone | +1 650 837-7000 |
| Fax | — |
| — | |
| Website | https://www.exelixis.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000939767 |
| Description | Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Additional info from NASDAQ: |
2026-05-14 20:30
📋 BOMBORA RISE FOUNDATION (Family foundation of the CEO of EXEL.) plans to sell 100K shares of EXELIXIS, INC. (at $50.91 each, total $5.1M) Filed: May 14, 2026 | ID: 004537
Read more
2026-05-08 23:03
Director Beckerle Mary C 🟡 adjusted position in 7.7K shares (1 derivative) of EXELIXIS, INC. (EXEL) at $48.45 Transaction Date: May 07, 2026 | Filing ID: 000063
Read more
2026-05-08 23:03
Director Freire Maria C 🟡 adjusted position in 20.6K shares (1 derivative) of EXELIXIS, INC. (EXEL) at $46.00 ($1.8M) Transaction Date: May 07, 2026 | Filing ID: 000062
Read more
2026-05-08 23:03
Director POSTE GEORGE 🔴 sold 60.0K shares of EXELIXIS, INC. (EXEL) at $45.71 ($2.7M) Transaction Date: May 07, 2026 | Filing ID: 000061
Read more
2026-05-08 23:03
Director MORRISSEY MICHAEL 🔴 sold 109.7K shares of EXELIXIS, INC. (EXEL) Transaction Date: May 06, 2026 | Filing ID: 000060
Read more
2026-05-07 20:39
📋 MARY BECKERLE (Director) plans to sell 8K shares of EXELIXIS, INC. (at $48.45 each, total $374K) Filed: May 07, 2026 | ID: 004211
Read more
2026-05-07 20:36
📋 GEORGE H POSTE (Director) plans to sell 60K shares of EXELIXIS, INC. (at $45.71 each, total $2.7M) Filed: May 07, 2026 | ID: 004210
Read more
2026-05-07 20:07
📋 MARIA C FREIRE (Director) plans to sell 21K shares of EXELIXIS, INC. (at $46.00 each, total $949K) Filed: May 07, 2026 | ID: 004180
Read more
2026-05-07 20:05
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01683110 | Expanded Access of Cabozantinib in Medullary Thyroid Cancer | — | Medullary Thyroid Cancer | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT00234481 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | Phase1 | Chronic Lymphocytic Leukemia | Terminated | — | — | ClinicalTrials.gov |
| NCT07283731 | Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced… | Phase2 | Phase 2 | Recruiting | 2026-06-02 | 2030-11-01 | ClinicalTrials.gov |
| NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningio… | Phase2 | Meningioma | Not_Yet_Recruiting | 2026-05-01 | 2029-09-01 | ClinicalTrials.gov |
| NCT07484139 | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytru… | Phase2 | Oral Cavity Squamous Cell Carcinoma | Not_Yet_Recruiting | 2026-05-01 | 2028-05-01 | ClinicalTrials.gov |
| NCT07218666 | Zanzalintinib in Men With Aggressive Variant Prostate Cancer | Phase2 | Aggressive Variant Prostate Carcinoma | Not_Yet_Recruiting | 2026-05-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07511504 | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Tre… | Phase2 | Locally Advanced Hepatocellular Carcinoma | Not_Yet_Recruiting | 2026-04-02 | 2027-08-01 | ClinicalTrials.gov |
| NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment… | Phase1 | Clear Cell Renal Cell Carcinoma | Not_Yet_Recruiting | 2026-03-31 | 2029-04-07 | ClinicalTrials.gov |
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Wh… | Phase2 | Advanced Renal Cell Carcinoma | Recruiting | 2026-03-13 | 2028-12-31 | ClinicalTrials.gov |
| NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatoce… | Phase2 | Hepatocellular Carcinoma | Not_Yet_Recruiting | 2026-02-01 | 2027-08-01 | ClinicalTrials.gov |
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | Phase2 | Advanced Urothelial Carcinoma | Not_Yet_Recruiting | 2026-02-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Met… | Phase1 | Metastatic Soft-tissue Sarcoma | Recruiting | 2026-01-05 | 2031-07-31 | ClinicalTrials.gov |
| NCT06926634 | Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms … | Phase2 | High Grade Neuroendocrine Neoplasms | Recruiting | 2025-12-09 | 2034-12-31 | ClinicalTrials.gov |
| NCT07193550 | A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) | Phase2 | Bone Sarcomas | Recruiting | 2025-12-05 | 2031-10-31 | ClinicalTrials.gov |
| NCT06937866 | Maintenance Zanzalintinib With Etoposide After HDCT in GCT | Phase1 | Germ Cell Tumor | Recruiting | 2025-11-12 | 2031-09-01 | ClinicalTrials.gov |
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/… | Phase2 | Locally Advanced Renal Cell Carcinoma | Recruiting | 2025-10-30 | 2029-06-06 | ClinicalTrials.gov |
| NCT06957431 | Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma | Phase1 | Advanced Leiomyosarcoma | Recruiting | 2025-10-22 | 2033-10-31 | ClinicalTrials.gov |
| NCT06795009 | Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Ca… | Phase1 | Uterine Cancer | Recruiting | 2025-10-17 | 2035-04-30 | ClinicalTrials.gov |
| NCT07043608 | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastas… | Phase2 | Clear Cell Renal Cell Cancer (ccRCC) | Not_Yet_Recruiting | 2025-09-30 | 2029-09-30 | ClinicalTrials.gov |
| NCT06912087 | Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head an… | Phase1 | Head and Neck Neoplasms | Recruiting | 2025-09-29 | 2027-06-05 | ClinicalTrials.gov |
| NCT07123103 | A Study of XB371 Administered in Participants With Locally Advanced or Metastat… | Phase1 | Solid Tumors | Recruiting | 2025-08-18 | 2028-02-01 | ClinicalTrials.gov |
| NCT06959511 | Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | Phase2 | Neoadjuvant Treatment | Recruiting | 2025-07-22 | 2030-10-01 | ClinicalTrials.gov |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metast… | Phase2 | Pancreatic Neuroendocrine Tumor (pNET) | Recruiting | 2025-07-21 | 2029-06-01 | ClinicalTrials.gov |
| NCT06902376 | XL092 and Cemiplimab in BRAF WT Thyroid Cancer | Phase1 | Anaplastic Thyroid Cancer | Recruiting | 2025-06-03 | 2028-08-31 | ClinicalTrials.gov |
| NCT06962332 | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate… | Phase1 | Hepatic Impairment | Recruiting | 2025-05-13 | 2026-04-01 | ClinicalTrials.gov |
| NCT06952010 | A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tu… | Phase1 | Solid Tumor | Recruiting | 2025-05-01 | 2027-11-30 | ClinicalTrials.gov |
| NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Ca… | Phase1 | Metastatic Renal Cell Carcinoma | Recruiting | 2025-02-14 | 2027-02-01 | ClinicalTrials.gov |
| NCT06698250 | Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatoc… | Phase2 | Hepatocellular Carcinoma | Recruiting | 2024-12-18 | 2027-04-30 | ClinicalTrials.gov |
| NCT06568562 | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase2 | Metastatic Castration-resistant Prostate Cancer | Recruiting | 2024-12-09 | 2028-12-01 | ClinicalTrials.gov |
| NCT05859217 | A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCL… | Phase2 | Lung Cancer | Not_Yet_Recruiting | 2024-12-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT06630247 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants W… | Phase1 | Solid Cancers | Terminated | 2024-10-17 | 2025-05-07 | ClinicalTrials.gov |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | Phase1 | Locally Advanced or Metastatic Solid Tumors | Recruiting | 2024-08-06 | 2027-10-20 | ClinicalTrials.gov |
| NCT06082167 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects Wit… | Phase2 | Head and Neck Squamous Cell Carcinoma | Active_Not_Recruiting | 2024-06-07 | 2029-03-01 | ClinicalTrials.gov |
| NCT05932862 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants Wit… | Phase1 | Advanced Solid Tumor | Recruiting | 2024-04-03 | 2029-08-03 | ClinicalTrials.gov |
| NCT06191796 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in… | Phase1 | Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors | Terminated | 2024-01-25 | 2025-05-12 | ClinicalTrials.gov |
| NCT05931393 | Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) | Phase2 | RCC | Recruiting | 2023-12-20 | 2028-12-31 | ClinicalTrials.gov |
| NCT06132945 | A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Re… | Phase1 | Metastatic Renal Cell Carcinoma | Active_Not_Recruiting | 2023-11-10 | 2027-11-01 | ClinicalTrials.gov |
| NCT06156410 | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | Phase1 | Ewing Sarcoma | Recruiting | 2023-10-24 | 2028-11-01 | ClinicalTrials.gov |
| NCT05613894 | Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-… | Phase1 | Metastatic Castration-resistant Prostate Cancer | Recruiting | 2023-07-14 | 2028-05-01 | ClinicalTrials.gov |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-… | Phase2 | Hepatocellular Carcinoma | Withdrawn | 2023-02-24 | 2023-05-03 | ClinicalTrials.gov |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate… | Phase2 | Castration-resistant Prostate Cancer | Recruiting | 2023-02-02 | 2027-04-12 | ClinicalTrials.gov |
| NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic… | Phase3 | Non-Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2023-01-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT05249114 | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Posi… | Phase1 | Neuroendocrine Tumors | Active_Not_Recruiting | 2022-12-28 | 2029-12-01 | ClinicalTrials.gov |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With… | Phase2 | Brain Metastases | Recruiting | 2022-09-20 | 2027-12-31 | ClinicalTrials.gov |
| NCT05425940 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Co… | Phase3 | Colorectal Cancer | Active_Not_Recruiting | 2022-09-07 | 2027-01-01 | ClinicalTrials.gov |
| NCT05135975 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurr… | Phase2 | Neuroblastoma | Recruiting | 2022-07-20 | 2029-12-01 | ClinicalTrials.gov |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Mel… | Phase2 | Refractory Cutaneous Melanoma | Terminated | 2022-06-08 | 2024-07-23 | ClinicalTrials.gov |
| NCT05425004 | Cabozantinib for Patients With Recurrent or Progressive Meningioma | Phase2 | Meningioma | Recruiting | 2022-06-01 | 2028-05-01 | ClinicalTrials.gov |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase1 | Non-Hodgkin's Lymphoma (NHL) | Terminated | 2022-04-12 | 2022-11-01 | ClinicalTrials.gov |
| NCT04919122 | Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Ren… | — | Metastatic Renal Cell Carcinoma | Active_Not_Recruiting | 2022-04-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell C… | Phase2 | Metastatic Renal Cell Carcinoma | Recruiting | 2022-01-21 | 2027-02-01 | ClinicalTrials.gov |
| NCT05052723 | Cabozantinib and Pembrolizumab in Metastatic Pancreas | Phase2 | Pancreatic Cancer | Completed | 2022-01-04 | 2024-11-05 | ClinicalTrials.gov |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participan… | Phase1 | Renal Cell Carcinoma (RCC) | Recruiting | 2021-12-14 | 2030-06-28 | ClinicalTrials.gov |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh… | Phase1 | Advanced Adult Hepatocellular Carcinoma | Terminated | 2021-08-06 | 2023-05-02 | ClinicalTrials.gov |
| NCT04878029 | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Met… | Phase1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | Recruiting | 2021-07-23 | 2028-12-21 | ClinicalTrials.gov |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Sta… | Phase2 | Colorectal Adenocarcinoma | Active_Not_Recruiting | 2021-06-23 | 2027-02-09 | ClinicalTrials.gov |
| NCT04876456 | A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | Phase2 | Germ Cell Tumor | Active_Not_Recruiting | 2021-06-10 | 2027-01-01 | ClinicalTrials.gov |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Phase1 | Non Small Cell Lung Cancer | Completed | 2021-06-07 | 2025-03-10 | ClinicalTrials.gov |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver C… | Phase2 | Advanced Hepatocellular Carcinoma | Terminated | 2021-04-20 | 2022-03-08 | ClinicalTrials.gov |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Ad… | Phase1 | Carcinoma, Non-small Cell Lung Cancer | Withdrawn | 2021-04-15 | 2026-05-13 | ClinicalTrials.gov |
| NCT04631744 | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mC… | Phase2 | Prostate Cancer | Completed | 2021-03-03 | 2025-11-09 | ClinicalTrials.gov |
| NCT04477512 | Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metasta… | Phase1 | Metastatic Hormone Refractory Prostate Cancer | Completed | 2021-02-19 | 2025-09-10 | ClinicalTrials.gov |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid T… | Phase1 | Neoplasm Malignant | Terminated | 2021-02-10 | 2024-05-02 | ClinicalTrials.gov |
| NCT04551430 | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue… | Phase2 | Metastatic Soft-tissue Sarcoma | Active_Not_Recruiting | 2021-01-05 | 2029-02-01 | ClinicalTrials.gov |
| NCT04412629 | Cabozantinib in High Grade Neuroendocrine Neoplasms | Phase2 | High Grade Neuroendocrine Neoplasms | Active_Not_Recruiting | 2020-11-24 | 2027-03-31 | ClinicalTrials.gov |
| NCT04413123 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Phase2 | Papillary Renal Cell Carcinoma | Active_Not_Recruiting | 2020-11-05 | 2026-12-20 | ClinicalTrials.gov |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Sub… | Phase3 | Metastatic Prostate Cancer | Active_Not_Recruiting | 2020-10-19 | 2026-10-16 | ClinicalTrials.gov |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Pati… | Phase3 | Carcinoma, Non-Small-Cell Lung | Completed | 2020-10-01 | 2025-01-17 | ClinicalTrials.gov |
| NCT04472767 | Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepat… | Phase2 | Hepatocellular Carcinoma | Recruiting | 2020-08-07 | 2027-09-01 | ClinicalTrials.gov |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantin… | Phase3 | Carcinoma, Renal Cell | Terminated | 2020-07-28 | 2025-03-24 | ClinicalTrials.gov |
| NCT04322955 | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase … | Phase2 | Kidney Cancer | Recruiting | 2020-06-22 | 2028-02-01 | ClinicalTrials.gov |
| NCT04220229 | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extrem… | Phase1 | Sarcoma of the Extremity | Terminated | 2020-06-01 | 2024-10-31 | ClinicalTrials.gov |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive Blad… | Phase2 | Bladder Cancer | Active_Not_Recruiting | 2020-05-21 | 2025-12-01 | ClinicalTrials.gov |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cer… | Phase2 | Cervical Cancer | Terminated | 2020-04-16 | 2022-02-16 | ClinicalTrials.gov |
| NCT03964337 | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With … | Phase2 | Prostate Cancer | Terminated | 2020-03-17 | 2021-06-04 | ClinicalTrials.gov |
| NCT04091750 | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced M… | Phase2 | Melanoma | Active_Not_Recruiting | 2020-03-02 | 2026-12-01 | ClinicalTrials.gov |
| NCT04164979 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastro… | Phase2 | Gastric Adenocarcinoma | Active_Not_Recruiting | 2020-02-04 | 2026-05-30 | ClinicalTrials.gov |
| NCT04197310 | Cabozantinib and Nivolumab for Carcinoid Tumors | Phase2 | Carcinoid Tumor | Completed | 2019-12-26 | 2024-01-31 | ClinicalTrials.gov |
| NCT03957551 | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | Phase1 | Advanced Metastatic Melanoma | Terminated | 2019-08-27 | 2025-10-17 | ClinicalTrials.gov |
| NCT03867045 | Development of a Cabozantinib (Cabometyx) Symptom Management Application for Us… | Na | Metastatic Renal Cell Carcinoma Treated With Cabozantinib | Terminated | 2019-08-21 | 2019-12-16 | ClinicalTrials.gov |
| NCT03899155 | Pan Tumor Rollover Study | Phase2 | Cancer | Recruiting | 2019-08-09 | 2029-08-25 | ClinicalTrials.gov |
| NCT04022343 | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Canc… | Phase2 | Clear Cell Renal Cell Carcinoma | Active_Not_Recruiting | 2019-08-06 | 2026-03-01 | ClinicalTrials.gov |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients … | Phase3 | Renal Cell Carcinoma | Active_Not_Recruiting | 2019-06-25 | 2027-01-31 | ClinicalTrials.gov |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid… | Phase1 | Neoplasm Malignant | Active_Not_Recruiting | 2019-03-20 | 2027-05-31 | ClinicalTrials.gov |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gast… | Phase1 | Gastric Cancer | Recruiting | 2018-10-22 | 2029-06-30 | ClinicalTrials.gov |
| NCT03690388 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refr… | Phase3 | Differentiated Thyroid Cancer | Active_Not_Recruiting | 2018-10-05 | 2026-07-31 | ClinicalTrials.gov |
| NCT03468218 | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | Phase2 | Metastatic Head and Neck Carcinoma | Active_Not_Recruiting | 2018-09-18 | 2026-10-29 | ClinicalTrials.gov |
| NCT03534804 | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible … | Phase2 | Metastatic Urothelial Carcinoma | Completed | 2018-09-18 | 2024-04-15 | ClinicalTrials.gov |
| NCT03611595 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed… | Phase1 | Solid Tumor | Recruiting | 2018-08-28 | 2027-08-01 | ClinicalTrials.gov |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Part… | Phase3 | Hepatocellular Carcinoma | Active_Not_Recruiting | 2018-06-10 | 2026-07-31 | ClinicalTrials.gov |
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Varia… | Phase2 | Malignant Neoplasms of Urinary Tract | Active_Not_Recruiting | 2018-05-15 | 2027-07-31 | ClinicalTrials.gov |
| NCT03299946 | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) … | Phase1 | Locally Advanced Hepatocellular Carcinoma | Completed | 2018-05-14 | 2021-10-01 | ClinicalTrials.gov |
| NCT03316586 | A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic T… | Phase2 | Breast Cancer | Completed | 2017-11-30 | 2019-08-30 | ClinicalTrials.gov |
| NCT03213626 | Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metas… | Phase2 | Pancreatic Adenocarcinoma Metastatic | Terminated | 2017-10-13 | 2019-11-18 | ClinicalTrials.gov |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects Wit… | Phase1 | Urothelial Carcinoma | Active_Not_Recruiting | 2017-09-05 | 2027-09-30 | ClinicalTrials.gov |
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previo… | Phase3 | Renal Cell Carcinoma | Active_Not_Recruiting | 2017-07-23 | 2026-01-16 | ClinicalTrials.gov |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Phase1 | Colorectal Adenocarcinoma | Completed | 2017-07-07 | 2021-06-10 | ClinicalTrials.gov |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tu… | Phase2 | Non-small Cell Lung Carcinoma | Completed | 2016-09-28 | 2022-08-17 | ClinicalTrials.gov |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Me… | Phase1 | Melanoma | Active_Not_Recruiting | 2016-09-07 | 2026-11-04 | ClinicalTrials.gov |
| NCT02132598 | Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastas… | Phase2 | Non Small Cell Lung Cancer (NSCLC) | Terminated | 2015-12-01 | 2019-08-09 | ClinicalTrials.gov |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastat… | Phase4 | Medullary Thyroid Cancer | Active_Not_Recruiting | 2015-02-25 | 2035-01-01 | ClinicalTrials.gov |
| NCT02260531 | Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases | Phase2 | Breast Cancer | Completed | 2014-11-01 | 2020-03-17 | ClinicalTrials.gov |
| NCT02036476 | Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma | Phase2 | Merkel Cell Carcinoma | Terminated | 2014-02-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone… | Phase2 | Prostate Cancer | Terminated | 2014-02-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01630590 | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastat… | Phase2 | Prostate Cancer | Completed | 2014-01-08 | 2021-04-06 | ClinicalTrials.gov |
| NCT02008383 | Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Canc… | Phase1 | Colorectal Cancer | Completed | 2014-01-01 | 2018-08-29 | ClinicalTrials.gov |
| NCT01961765 | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Mye… | Phase1 | Relapsed Acute Myeloid Leukemia | Completed | 2013-11-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcin… | Phase3 | Hepatocellular Carcinoma | Completed | 2013-09-26 | 2021-01-12 | ClinicalTrials.gov |
| NCT01954745 | Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma | Phase2 | Bile Duct Cancer | Completed | 2013-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal… | Phase3 | Renal Cell Carcinoma | Completed | 2013-06-01 | 2021-01-15 | ClinicalTrials.gov |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | Phase1 | Relapsed or Refractory Multiple Myeloma | Completed | 2013-05-28 | 2016-08-18 | ClinicalTrials.gov |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Phase2 | Poorly Differentiated Thyroid Gland Carcinoma | Completed | 2013-05-08 | 2017-10-09 | ClinicalTrials.gov |
| NCT01761773 | A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Caps… | Phase1 | Healthy | Completed | 2012-12-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01657591 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Sta… | Phase1 | Melanoma | Completed | 2012-07-27 | 2021-09-21 | ClinicalTrials.gov |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castrati… | Phase3 | Prostate Cancer | Completed | 2012-07-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT01639508 | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung … | Phase2 | Non-Small Cell Lung Cancer | Recruiting | 2012-07-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With P… | Phase3 | Prostate Cancer | Terminated | 2012-03-01 | 2015-01-13 | ClinicalTrials.gov |
| NCT01428219 | Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic … | Phase2 | Prostate Cancer Metastatic | Terminated | 2012-02-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01441947 | Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer | Phase2 | Breast Cancer | Completed | 2011-10-01 | 2019-08-09 | ClinicalTrials.gov |
| NCT01493869 | Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaire… | Phase1 | Healthy | Completed | 2011-09-01 | 2014-08-01 | ClinicalTrials.gov |
| NCT01553656 | Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced C… | Phase1 | Solid Tumors | Completed | 2011-02-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosigli… | Phase1 | Papillary Thyroid Cancer | Completed | 2010-04-01 | — | ClinicalTrials.gov |
| NCT01068782 | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocyti… | Phase2 | Astrocytic Tumors | Terminated | 2010-04-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00927875 | A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alo… | Phase1 | Small Cell Lung Carcinoma | Completed | 2010-02-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT00909402 | A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic… | Phase1 | Stomach Neoplasms | Completed | 2009-11-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00940225 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | Phase2 | Solid Tumors | Completed | 2009-09-01 | 2014-06-01 | ClinicalTrials.gov |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radia… | Phase1 | Glioblastoma | Completed | 2009-09-01 | 2013-10-01 | ClinicalTrials.gov |
| NCT00884546 | Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma | Phase1 | Advanced Cancer, Various, NOS | Completed | 2009-07-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | Phase1 | Advanced Solid Cancers | Terminated | 2009-05-31 | 2010-08-04 | ClinicalTrials.gov |
| NCT00838890 | A Study of BMS-863233 in Patients With Hematologic Cancer | Phase1 | Refractory Hematologic Cancer | Terminated | 2009-03-01 | 2010-01-01 | ClinicalTrials.gov |
| NCT00796484 | Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors | Phase1 | Cancer | Terminated | 2008-11-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00670189 | A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic C… | Phase1 | Hedgehog Pathway | Completed | 2008-07-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT00704392 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults Wit… | Phase1 | Cancer | Withdrawn | 2008-06-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | Phase3 | Thyroid Cancer | Completed | 2008-06-01 | 2020-09-01 | ClinicalTrials.gov |
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | Phase2 | Glioblastoma Multiforme | Completed | 2008-05-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT00596648 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-… | Phase1 | Carcinoma, Non-Small-Cell Lung | Completed | 2008-02-12 | 2012-08-02 | ClinicalTrials.gov |
| NCT00570635 | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and… | Phase2 | Gastrointestinal Stromal Tumors | Completed | 2007-12-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | Phase1 | Polycythemia Vera | Terminated | 2007-12-01 | 2009-02-01 | ClinicalTrials.gov |
| NCT00526838 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies | Phase1 | Cancer | Terminated | 2007-09-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | Phase1 | Myeloproliferative Disorders | Terminated | 2007-08-01 | — | ClinicalTrials.gov |
| NCT00475917 | A Study of XL844 Administered as a Single Agent and in Combination With Gemcita… | Phase1 | Cancer | Terminated | 2007-05-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromo… | Phase1 | Chronic Myeloid Leukemia | Terminated | 2007-05-01 | 2011-04-01 | ClinicalTrials.gov |
| NCT00460278 | Study of XL418 in Adults With Solid Tumors | Phase1 | Cancer | Suspended | 2007-04-01 | — | ClinicalTrials.gov |
| NCT00451880 | Study of XL281 in Adults With Solid Tumors | Phase1 | Cancer | Completed | 2007-02-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00350831 | Study of XL820 Given Orally Daily to Subjects With Solid Tumors | Phase1 | Cancer | Completed | 2006-07-01 | — | ClinicalTrials.gov |
| NCT00215605 | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies | Phase1 | Lymphoma | Completed | 2005-09-01 | 2012-07-01 | ClinicalTrials.gov |
| NCT00129571 | Study of XL820 in Adults With Solid Tumors | Phase1 | Cancer | Completed | 2005-08-01 | — | ClinicalTrials.gov |
Total clinical trials: 147
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| XB628 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06952010 |
| Cabozantinib | Other | Phase PHASE2 | Meningioma | RECRUITING | NCT05425004 |
| XL418 | Other | Phase PHASE1 | Cancer | SUSPENDED | NCT00460278 |
| XL418 | Other | Phase PHASE1 | Cancer | SUSPENDED | NCT00460278 |
| XL844 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00234481 |
| XL844 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT00234481 |
| XL820 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00129571 |
| XL820 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00129571 |
| XL820 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00350831 |
| XB628 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06952010 |
| Cabozantinib | Other | Phase PHASE2 | Meningioma | RECRUITING | NCT05425004 |
| famotidine | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00451880 |
| XL281 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00451880 |
| famotidine | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00451880 |
| XL281 | Other | Phase PHASE1 | Cancer | COMPLETED | NCT00451880 |
| XB628 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06952010 |
| Cabozantinib | Other | Phase PHASE2 | Meningioma | RECRUITING | NCT05425004 |
| cabozantinib | Other | Preclinical | Medullary Thyroid Cancer | APPROVED_FOR_MARKETING | NCT01683110 |
| cabozantinib | Other | Preclinical | Medullary Thyroid Cancer | APPROVED_FOR_MARKETING | NCT01683110 |
| XL184 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00215605 |
| XL184 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00215605 |
| XL184 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00215605 |
| XL820 | Other | Phase PHASE2 | Gastrointestinal Stromal Tumors | COMPLETED | NCT00570635 |
| XL820 | Other | Phase PHASE2 | Gastrointestinal Stromal Tumors | COMPLETED | NCT00570635 |
| XL184 | Other | Phase PHASE1 | Papillary Thyroid Cancer | COMPLETED | NCT01100619 |
| rosiglitazone | Other | Phase PHASE1 | Papillary Thyroid Cancer | COMPLETED | NCT01100619 |
| XL184 | Other | Phase PHASE1 | Papillary Thyroid Cancer | COMPLETED | NCT01100619 |
| rosiglitazone | Other | Phase PHASE1 | Papillary Thyroid Cancer | COMPLETED | NCT01100619 |
| cabozantinib | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01761773 |
| cabozantinib | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01761773 |
| cabozantinib | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01493869 |
| cabozantinib | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01493869 |
| cabozantinib | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01493869 |
| Radiation Therapy | Drug | Phase PHASE1 | Glioblastoma | COMPLETED | NCT00960492 |
| temozolomide | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT00960492 |
| XL184 | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT00960492 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01605227 |
| cabozantinib | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01605227 |
| cabozantinib tablets | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01553656 |
| cabozantinib capsules | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01553656 |
| cabozantinib tablets | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01553656 |
| cabozantinib capsules | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT01553656 |
| XL147 | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT00704392 |
| XL647 | Other | Phase PHASE1 | Cancer | WITHDRAWN | NCT00704392 |
| XL888 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00796484 |
| XL888 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00796484 |
| XL019 | Other | Phase PHASE1 | Polycythemia Vera | TERMINATED | NCT00595829 |
| XL019 | Other | Phase PHASE1 | Polycythemia Vera | TERMINATED | NCT00595829 |
| XL228 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00526838 |
| Gemcitabine | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00475917 |
| XL844 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00475917 |
| Gemcitabine | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00475917 |
| XL844 | Other | Phase PHASE1 | Cancer | TERMINATED | NCT00475917 |
| XL228 | Other | Phase PHASE1 | Chronic Myeloid Leukemia | TERMINATED | NCT00464113 |
| XL228 | Other | Phase PHASE1 | Chronic Myeloid Leukemia | TERMINATED | NCT00464113 |
| Cabozantinib | Other | Phase PHASE2 | Bile Duct Cancer | COMPLETED | NCT01954745 |
| cabozantinib | Other | Phase PHASE1 | Relapsed Acute Myeloid Leukemia | COMPLETED | NCT01961765 |
| Cabozantinib (XL184) | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT01866293 |
| Cabozantinib (XL184) | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma | COMPLETED | NCT01866293 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer Metastatic | TERMINATED | NCT01428219 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer Metastatic | TERMINATED | NCT01428219 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01605227 |
| cabozantinib | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01605227 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01605227 |
| cabozantinib | Other | Phase PHASE3 | Prostate Cancer | COMPLETED | NCT01605227 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Poorly Differentiated Thyroid Gland Carcinoma | COMPLETED | NCT01811212 |
| Cabozantinib S-malate | Other | Phase PHASE2 | Poorly Differentiated Thyroid Gland Carcinoma | COMPLETED | NCT01811212 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| mitoxantrone | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| cabozantinib | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| mitoxantrone | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| cabozantinib | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| prednisone | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| mitoxantrone | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| cabozantinib | Other | Phase PHASE3 | Prostate Cancer | TERMINATED | NCT01522443 |
| Erlotinib 100Mg Tab | Other | Phase PHASE2 | Pancreatic Adenocarcinoma Metastatic | TERMINATED | NCT03213626 |
| Cabozantinib 40 MG | Other | Phase PHASE2 | Pancreatic Adenocarcinoma Metastatic | TERMINATED | NCT03213626 |
| Erlotinib 100Mg Tab | Other | Phase PHASE2 | Pancreatic Adenocarcinoma Metastatic | TERMINATED | NCT03213626 |
| Cabozantinib 40 MG | Other | Phase PHASE2 | Pancreatic Adenocarcinoma Metastatic | TERMINATED | NCT03213626 |
| Cabozantinib | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT02008383 |
| Panitumumab | Other | Phase PHASE1 | Colorectal Cancer | COMPLETED | NCT02008383 |
| cabozantinib | Other | Phase PHASE2 | Non Small Cell Lung Cancer (NSCLC) | TERMINATED | NCT02132598 |
| cabozantinib | Other | Phase PHASE2 | Non Small Cell Lung Cancer (NSCLC) | TERMINATED | NCT02132598 |
| cabozantinib | Other | Phase PHASE2 | Non Small Cell Lung Cancer (NSCLC) | TERMINATED | NCT02132598 |
| Usability of an electronic symptom management application | Other | Approved | Metastatic Renal Cell Carcinoma Treated With Cabozantinib | TERMINATED | NCT03867045 |
| Usability of an electronic symptom management application | Other | Approved | Metastatic Renal Cell Carcinoma Treated With Cabozantinib | TERMINATED | NCT03867045 |
| Vemurafenib | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01657591 |
| XL888 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01657591 |
| Placebo | Other | Phase PHASE3 | Thyroid Cancer | COMPLETED | NCT00704730 |
| XL184 | Other | Phase PHASE3 | Thyroid Cancer | COMPLETED | NCT00704730 |
| Placebo | Other | Phase PHASE3 | Thyroid Cancer | COMPLETED | NCT00704730 |
| XL184 | Other | Phase PHASE3 | Thyroid Cancer | COMPLETED | NCT00704730 |
| Everolimus (Afinitor) tablets | Other | Phase PHASE3 | Renal Cell Carcinoma | COMPLETED | NCT01865747 |
| Cabozantinib tablets | Other | Phase PHASE3 | Renal Cell Carcinoma | COMPLETED | NCT01865747 |
| Everolimus (Afinitor) tablets | Other | Phase PHASE3 | Renal Cell Carcinoma | COMPLETED | NCT01865747 |
| Cabozantinib tablets | Other | Phase PHASE3 | Renal Cell Carcinoma | COMPLETED | NCT01865747 |
| Placebo tablets | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT01908426 |
| Cabozantinib tablets | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT01908426 |
| Placebo tablets | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT01908426 |
| Cabozantinib tablets | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT01908426 |
| Placebo tablets | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT01908426 |
| Cabozantinib tablets | Other | Phase PHASE3 | Hepatocellular Carcinoma | COMPLETED | NCT01908426 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02260531 |
| Cabozantinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02260531 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02260531 |
| Cabozantinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02260531 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02260531 |
| Cabozantinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02260531 |
| Androgen Ablation Therapy | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01630590 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01630590 |
| Androgen Ablation Therapy | Drug | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01630590 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT01630590 |
| Pembrolizumab 200 mg IV every 3 weeks | Other | Phase PHASE2 | Cervical Cancer | TERMINATED | NCT04230954 |
| Cabozantinib 40 MG oral once a day | Other | Phase PHASE2 | Cervical Cancer | TERMINATED | NCT04230954 |
| Radical Prostatectomy | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03964337 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03964337 |
| Radical Prostatectomy | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03964337 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03964337 |
| Radical Prostatectomy | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03964337 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT03964337 |
| Vemurafenib | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01657591 |
| XL888 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01657591 |
| Vemurafenib | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01657591 |
| XL888 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01657591 |
| Pembrolizumab | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | TERMINATED | NCT04442581 |
| Cabozantinib S-malate | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | TERMINATED | NCT04442581 |
| Pembrolizumab | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | TERMINATED | NCT04442581 |
| Cabozantinib S-malate | Other | Phase PHASE2 | Advanced Hepatocellular Carcinoma | TERMINATED | NCT04442581 |
| Cabozantinib | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT02036476 |
| Cabozantinib | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT02036476 |
| Cabozantinib | Other | Phase PHASE2 | Merkel Cell Carcinoma | TERMINATED | NCT02036476 |
| Nivolumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | WITHDRAWN | NCT05039736 |
| Cabozantinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | WITHDRAWN | NCT05039736 |
| Nivolumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | WITHDRAWN | NCT05039736 |
| Cabozantinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | WITHDRAWN | NCT05039736 |
| XL114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma (NHL) | TERMINATED | NCT05144347 |
| XL114 | Other | Phase PHASE1 | Non-Hodgkin's Lymphoma (NHL) | TERMINATED | NCT05144347 |
| XL184 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00704288 |
| XL184 | Other | Phase PHASE2 | Glioblastoma Multiforme | COMPLETED | NCT00704288 |
| Placebo | Other | Phase PHASE2 | Solid Tumors | COMPLETED | NCT00940225 |
| Cabozantinib | Other | Phase PHASE2 | Solid Tumors | COMPLETED | NCT00940225 |
| Placebo | Other | Phase PHASE2 | Solid Tumors | COMPLETED | NCT00940225 |
| Cabozantinib | Other | Phase PHASE2 | Solid Tumors | COMPLETED | NCT00940225 |
| Atezolizumab | Other | Phase PHASE2 | Lung Cancer | NOT_YET_RECRUITING | NCT05859217 |
| Cabozantinib | Other | Phase PHASE2 | Lung Cancer | NOT_YET_RECRUITING | NCT05859217 |
| Atezolizumab | Other | Phase PHASE2 | Lung Cancer | NOT_YET_RECRUITING | NCT05859217 |
| Cabozantinib | Other | Phase PHASE2 | Lung Cancer | NOT_YET_RECRUITING | NCT05859217 |
| Prednisone | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| Abiraterone | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| Fulvestrant | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| XL102 | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| Prednisone | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| Abiraterone | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| Fulvestrant | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| XL102 | Other | Phase PHASE1 | Neoplasm Malignant | TERMINATED | NCT04726332 |
| Cabozantinib | Other | Phase PHASE1 | Advanced Adult Hepatocellular Carcinoma | TERMINATED | NCT04497038 |
| Cabozantinib | Other | Phase PHASE1 | Advanced Adult Hepatocellular Carcinoma | TERMINATED | NCT04497038 |
| Cabozantinib | Other | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT05135975 |
| Eribulin | Other | Phase PHASE1 | Advanced Leiomyosarcoma | RECRUITING | NCT06957431 |
| Zanzalintinib | Other | Phase PHASE1 | Advanced Leiomyosarcoma | RECRUITING | NCT06957431 |
| Eribulin | Other | Phase PHASE1 | Advanced Leiomyosarcoma | RECRUITING | NCT06957431 |
| Zanzalintinib | Other | Phase PHASE1 | Advanced Leiomyosarcoma | RECRUITING | NCT06957431 |
| Pembrolizumab | Other | Phase PHASE2 | Phase 2 | RECRUITING | NCT07283731 |
| Zanzalintinib | Other | Phase PHASE2 | Phase 2 | RECRUITING | NCT07283731 |
| Pembrolizumab | Other | Phase PHASE2 | Phase 2 | RECRUITING | NCT07283731 |
| Zanzalintinib | Other | Phase PHASE2 | Phase 2 | RECRUITING | NCT07283731 |
| Avelumab | Other | Phase PHASE1 | Neoplasm Malignant | ACTIVE_NOT_RECRUITING | NCT03845166 |
| Atezolizumab | Other | Phase PHASE1 | Neoplasm Malignant | ACTIVE_NOT_RECRUITING | NCT03845166 |
| XL092 | Other | Phase PHASE1 | Neoplasm Malignant | ACTIVE_NOT_RECRUITING | NCT03845166 |
| Avelumab | Other | Phase PHASE1 | Neoplasm Malignant | ACTIVE_NOT_RECRUITING | NCT03845166 |
| Atezolizumab | Other | Phase PHASE1 | Neoplasm Malignant | ACTIVE_NOT_RECRUITING | NCT03845166 |
| XL092 | Other | Phase PHASE1 | Neoplasm Malignant | ACTIVE_NOT_RECRUITING | NCT03845166 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Carcinoma | COMPLETED | NCT03534804 |
| Cabozantinib | Other | Phase PHASE2 | Metastatic Urothelial Carcinoma | COMPLETED | NCT03534804 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Urothelial Carcinoma | COMPLETED | NCT03534804 |
| Cabozantinib | Other | Phase PHASE2 | Metastatic Urothelial Carcinoma | COMPLETED | NCT03534804 |
| Cystectomy | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04289779 |
| Atezolizumab | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04289779 |
| Cabozantinib | Other | Phase PHASE2 | Bladder Cancer | ACTIVE_NOT_RECRUITING | NCT04289779 |
| Lu-177 | Other | Phase PHASE1 | Neuroendocrine Tumors | ACTIVE_NOT_RECRUITING | NCT05249114 |
| Cabozantinib | Other | Phase PHASE1 | Neuroendocrine Tumors | ACTIVE_NOT_RECRUITING | NCT05249114 |
| Bevacizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT04925284 |
| Nivolumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT04925284 |
| XB002 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT04925284 |
| Bevacizumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT04925284 |
| Nivolumab | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT04925284 |
| XB002 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT04925284 |
| Transarterial Chemoembolization | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Cabozantinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Ipilimumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Nivolumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Transarterial Chemoembolization | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Cabozantinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Ipilimumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Nivolumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT04472767 |
| Fulvestrant | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01441947 |
| Cabozantinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01441947 |
| Fulvestrant | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01441947 |
| Cabozantinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01441947 |
| Zanzalintinib | Other | Phase PHASE1 | Hepatic Impairment | RECRUITING | NCT06962332 |
| ADC cytotoxic agents | Other | Phase PHASE1 | Solid Cancers | TERMINATED | NCT06630247 |
| XL495 | Other | Phase PHASE1 | Solid Cancers | TERMINATED | NCT06630247 |
| ADC cytotoxic agents | Other | Phase PHASE1 | Solid Cancers | TERMINATED | NCT06630247 |
| XL495 | Other | Phase PHASE1 | Solid Cancers | TERMINATED | NCT06630247 |
| ADC cytotoxic agents | Other | Phase PHASE1 | Solid Cancers | TERMINATED | NCT06630247 |
| XL495 | Other | Phase PHASE1 | Solid Cancers | TERMINATED | NCT06630247 |
| Computerized tomography (CT) Scan | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Bone Scan | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Non-Investigational Radiation Therapy (RT) | Drug | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Investigator Choice of Bone Strengthening Agents (BSA) | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Zanzalintinib | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Computerized tomography (CT) Scan | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Bone Scan | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Non-Investigational Radiation Therapy (RT) | Drug | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Investigator Choice of Bone Strengthening Agents (BSA) | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Zanzalintinib | Other | Phase PHASE2 | Clear Cell Renal Cell Cancer (ccRCC) | NOT_YET_RECRUITING | NCT07043608 |
| Sunitinib Malate | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| Nivolumab | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| XL092 | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| Sunitinib Malate | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| Nivolumab | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| XL092 | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| Sunitinib Malate | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| Nivolumab | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| XL092 | Other | Phase PHASE3 | Non-Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT05678673 |
| Radiation Therapy | Drug | Phase PHASE1 | Sarcoma of the Extremity | TERMINATED | NCT04220229 |
| Cabozantinib S-malate | Other | Phase PHASE1 | Sarcoma of the Extremity | TERMINATED | NCT04220229 |
| Pembrolizumab | Other | Phase PHASE2 | Gastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04164979 |
| Cabozantinib | Other | Phase PHASE2 | Gastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04164979 |
| Pembrolizumab | Other | Phase PHASE2 | Gastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04164979 |
| Cabozantinib | Other | Phase PHASE2 | Gastric Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04164979 |
| Cabozantinib | Other | Phase PHASE2 | Neuroblastoma | RECRUITING | NCT05135975 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06082167 |
| Zanzalintinib-matched Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06082167 |
| Zanzalintinib | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06082167 |
| Pembrolizumab | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06082167 |
| Zanzalintinib-matched Placebo | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06082167 |
| Zanzalintinib | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06082167 |
| atezolizumab | Other | Phase PHASE1 | Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT03170960 |
| cabozantinib | Other | Phase PHASE1 | Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT03170960 |
| atezolizumab | Other | Phase PHASE1 | Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT03170960 |
| cabozantinib | Other | Phase PHASE1 | Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT03170960 |
| atezolizumab | Other | Phase PHASE1 | Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT03170960 |
| cabozantinib | Other | Phase PHASE1 | Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT03170960 |
| 13-cis-retinoic acid | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT03611595 |
| Cabozantinib | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT03611595 |
| 13-cis-retinoic acid | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT03611595 |
| Cabozantinib | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT03611595 |
| Placebo capsule | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Placebo tablet | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Cabozantinib (XL184) 60 mg | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Cabozantinib (XL184) 140 mg | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Placebo capsule | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Placebo tablet | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Cabozantinib (XL184) 60 mg | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Cabozantinib (XL184) 140 mg | Other | Phase PHASE4 | Medullary Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT01896479 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05932862 |
| XL309 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05932862 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05932862 |
| XL309 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT05932862 |
| Cabozantinib-matched placebo | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Ipilimumab | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Nivolumab | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Cabozantinib | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Cabozantinib-matched placebo | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Ipilimumab | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Nivolumab | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Cabozantinib | Other | Phase PHASE3 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT03937219 |
| Nivolumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | NOT_YET_RECRUITING | NCT07187869 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | NOT_YET_RECRUITING | NCT07187869 |
| Nivolumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | NOT_YET_RECRUITING | NCT07187869 |
| Cabozantinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | NOT_YET_RECRUITING | NCT07187869 |
| Placebo | Other | Phase PHASE3 | Differentiated Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT03690388 |
| Cabozantinib | Other | Phase PHASE3 | Differentiated Thyroid Cancer | ACTIVE_NOT_RECRUITING | NCT03690388 |
| Cabozantinib 80 MG | Other | Phase PHASE2 | RCC | RECRUITING | NCT05931393 |
| Cabozantinib 80 MG | Other | Phase PHASE2 | RCC | RECRUITING | NCT05931393 |
| Cabozantinib 80 MG | Other | Phase PHASE2 | RCC | RECRUITING | NCT05931393 |
| Zanzalintinib | Other | Phase PHASE2 | Aggressive Variant Prostate Carcinoma | NOT_YET_RECRUITING | NCT07218666 |
| Regorafenib | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05425940 |
| Atezolizumab | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05425940 |
| XL092 | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05425940 |
| Regorafenib | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05425940 |
| Atezolizumab | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05425940 |
| XL092 | Other | Phase PHASE3 | Colorectal Cancer | ACTIVE_NOT_RECRUITING | NCT05425940 |
| Cabozantinib | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05613894 |
| Cabozantinib | Other | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT05613894 |
| Tremelimumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Durvalumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Zanzalintinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Tremelimumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Durvalumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Zanzalintinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Tremelimumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Durvalumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Zanzalintinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | RECRUITING | NCT06698250 |
| Zanzalintinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07226063 |
| Durvalumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07226063 |
| Zanzalintinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07226063 |
| Durvalumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07226063 |
| Zanzalintinib | Other | Phase PHASE2 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07226063 |
| Durvalumab | Other | Phase PHASE2 | Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07226063 |
| Cabozantinib | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT06156410 |
| Cabozantinib | Other | Phase PHASE1 | Ewing Sarcoma | RECRUITING | NCT06156410 |
| Stereotactic Radiosurgery (SRS) | Procedure | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Cabozantinib | Other | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Stereotactic Radiosurgery (SRS) | Procedure | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Cabozantinib | Other | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Stereotactic Radiosurgery (SRS) | Procedure | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Cabozantinib | Other | Phase PHASE1 | Metastatic Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT06132945 |
| Pembrolizumab | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT05052723 |
| Cabozantinib | Other | Phase PHASE2 | Pancreatic Cancer | COMPLETED | NCT05052723 |
| Etoposide Capsule | Other | Phase PHASE1 | Germ Cell Tumor | RECRUITING | NCT06937866 |
| Zanzalintinib | Other | Phase PHASE1 | Germ Cell Tumor | RECRUITING | NCT06937866 |
| Pembrolizumab | Other | Phase PHASE1 | Head and Neck Neoplasms | RECRUITING | NCT06912087 |
| Cetuximab | Other | Phase PHASE1 | Head and Neck Neoplasms | RECRUITING | NCT06912087 |
| Zanzalintinib | Other | Phase PHASE1 | Head and Neck Neoplasms | RECRUITING | NCT06912087 |
| Nivolumab | Other | Phase PHASE2 | Metastatic Renal Cell Carcinoma | RECRUITING | NCT05263050 |
| Cabozantinib | Other | Phase PHASE2 | Metastatic Renal Cell Carcinoma | RECRUITING | NCT05263050 |
| XL092 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06568562 |
| XL092 | Other | Phase PHASE2 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06568562 |
| Paclitaxel | Other | Phase PHASE1 | Uterine Cancer | RECRUITING | NCT06795009 |
| Zanzalintinib | Other | Phase PHASE1 | Uterine Cancer | RECRUITING | NCT06795009 |
| Paclitaxel | Other | Phase PHASE1 | Uterine Cancer | RECRUITING | NCT06795009 |
| Zanzalintinib | Other | Phase PHASE1 | Uterine Cancer | RECRUITING | NCT06795009 |
| Paclitaxel | Other | Phase PHASE1 | Uterine Cancer | RECRUITING | NCT06795009 |
| Zanzalintinib | Other | Phase PHASE1 | Uterine Cancer | RECRUITING | NCT06795009 |
| Atezolizumab | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Sorafenib | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Cabozantinib | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Atezolizumab | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Sorafenib | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Cabozantinib | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Atezolizumab | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Sorafenib | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Cabozantinib | Other | Phase PHASE3 | Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | NCT03755791 |
| Zanzalintinib | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | RECRUITING | NCT06926634 |
| Zanzalintinib | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | RECRUITING | NCT06926634 |
| Cabozantinib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT01639508 |
| Cabozantinib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT01639508 |
| Cabozantinib | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT01639508 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT04631744 |
| Cabozantinib | Other | Phase PHASE2 | Prostate Cancer | COMPLETED | NCT04631744 |
| Prednisone | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Abiraterone Acetate | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Atezolizumab | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Prednisone | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Enzalutamide | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Abiraterone Acetate | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Atezolizumab | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Cabozantinib | Other | Phase PHASE3 | Metastatic Prostate Cancer | ACTIVE_NOT_RECRUITING | NCT04446117 |
| Docetaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04471428 |
| Atezolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04471428 |
| Cabozantinib | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04471428 |
| Docetaxel | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04471428 |
| Atezolizumab | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04471428 |
| Cabozantinib | Other | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT04471428 |
| Zanzalintinib | Other | Phase PHASE2 | Advanced Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07185945 |
| Zanzalintinib | Other | Phase PHASE2 | Advanced Urothelial Carcinoma | NOT_YET_RECRUITING | NCT07185945 |
| XB628 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06952010 |
| XB628 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06952010 |
| Cabozantinib | Other | Phase PHASE2 | Clear Cell Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | NCT04022343 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Soft-tissue Sarcoma | RECRUITING | NCT06968988 |
| Ipilimumab | Other | Phase PHASE1 | Metastatic Soft-tissue Sarcoma | RECRUITING | NCT06968988 |
| Zanzalintinib | Other | Phase PHASE1 | Metastatic Soft-tissue Sarcoma | RECRUITING | NCT06968988 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Soft-tissue Sarcoma | RECRUITING | NCT06968988 |
| Ipilimumab | Other | Phase PHASE1 | Metastatic Soft-tissue Sarcoma | RECRUITING | NCT06968988 |
| Zanzalintinib | Other | Phase PHASE1 | Metastatic Soft-tissue Sarcoma | RECRUITING | NCT06968988 |
| prednisone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| abiraterone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| cabozantinib | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| prednisone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| abiraterone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| cabozantinib | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| prednisone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| abiraterone | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| cabozantinib | Other | Phase PHASE2 | Prostate Cancer | TERMINATED | NCT01995058 |
| Sunitinib Malate | Other | Phase PHASE2 | Malignant Neoplasms of Urinary Tract | ACTIVE_NOT_RECRUITING | NCT03541902 |
| Cabozantinib | Other | Phase PHASE2 | Malignant Neoplasms of Urinary Tract | ACTIVE_NOT_RECRUITING | NCT03541902 |
| Sunitinib Malate | Other | Phase PHASE2 | Malignant Neoplasms of Urinary Tract | ACTIVE_NOT_RECRUITING | NCT03541902 |
| Cabozantinib | Other | Phase PHASE2 | Malignant Neoplasms of Urinary Tract | ACTIVE_NOT_RECRUITING | NCT03541902 |
| erlotinib | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT00596648 |
| XL184 | Other | Phase PHASE1 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT00596648 |
| Cabozantinib | Other | Phase PHASE2 | Germ Cell Tumor | ACTIVE_NOT_RECRUITING | NCT04876456 |
| Cabozantinib | Other | Phase PHASE2 | Germ Cell Tumor | ACTIVE_NOT_RECRUITING | NCT04876456 |
| Questionnaire Administration | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Quality-of-Life Assessment | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Enfortumab Vedotin | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Cabozantinib S-malate | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Questionnaire Administration | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Quality-of-Life Assessment | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Enfortumab Vedotin | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Cabozantinib S-malate | Other | Phase PHASE1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation | RECRUITING | NCT04878029 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Head and Neck Carcinoma | ACTIVE_NOT_RECRUITING | NCT03468218 |
| Cabozantinib | Other | Phase PHASE2 | Metastatic Head and Neck Carcinoma | ACTIVE_NOT_RECRUITING | NCT03468218 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Head and Neck Carcinoma | ACTIVE_NOT_RECRUITING | NCT03468218 |
| Cabozantinib | Other | Phase PHASE2 | Metastatic Head and Neck Carcinoma | ACTIVE_NOT_RECRUITING | NCT03468218 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Metastatic Melanoma | TERMINATED | NCT03957551 |
| Cabozantinib | Other | Phase PHASE1 | Advanced Metastatic Melanoma | TERMINATED | NCT03957551 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Metastatic Melanoma | TERMINATED | NCT03957551 |
| Cabozantinib | Other | Phase PHASE1 | Advanced Metastatic Melanoma | TERMINATED | NCT03957551 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Metastatic Melanoma | TERMINATED | NCT03957551 |
| Cabozantinib | Other | Phase PHASE1 | Advanced Metastatic Melanoma | TERMINATED | NCT03957551 |
| XB371 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07123103 |
| XB371 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07123103 |
| XB371 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07123103 |
| Zanzalintinib | Other | Phase PHASE2 | Meningioma | NOT_YET_RECRUITING | NCT07428616 |
| Zanzalintinib | Other | Phase PHASE2 | Meningioma | NOT_YET_RECRUITING | NCT07428616 |
| Cabozantinib | Other | Phase PHASE2 | Astrocytic Tumors | TERMINATED | NCT01068782 |
| Zanzalintinib | Other | Phase PHASE2 | Bone Sarcomas | RECRUITING | NCT07193550 |
| Zanzalintinib | Other | Phase PHASE2 | Bone Sarcomas | RECRUITING | NCT07193550 |
| Cobimetinib | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT02721459 |
| Vemurafenib | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT02721459 |
| XL888 | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT02721459 |
| Cobimetinib | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT02721459 |
| Vemurafenib | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT02721459 |
| XL888 | Other | Phase PHASE1 | Melanoma | ACTIVE_NOT_RECRUITING | NCT02721459 |
| Cabozantinib | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Ipilimumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Nivolumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Cabozantinib | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Ipilimumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Nivolumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Cabozantinib | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Ipilimumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Nivolumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Cabozantinib | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Ipilimumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Nivolumab | Other | Phase PHASE2 | Melanoma | ACTIVE_NOT_RECRUITING | NCT04091750 |
| Cabozantinib | Other | Phase PHASE2 | Meningioma | RECRUITING | NCT05425004 |
| Nivolumab + Relatlimab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Ipilimumab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Nivolumab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Zanzalintinib | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Nivolumab + Relatlimab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Ipilimumab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Nivolumab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Zanzalintinib | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Nivolumab + Relatlimab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Ipilimumab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Nivolumab | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Zanzalintinib | Other | Phase PHASE1 | Renal Cell Carcinoma (RCC) | RECRUITING | NCT05176483 |
| Cabozantinib | Other | Phase PHASE3 | Carcinoma, Renal Cell | TERMINATED | NCT04338269 |
| Atezolizumab | Other | Phase PHASE3 | Carcinoma, Renal Cell | TERMINATED | NCT04338269 |
| Cabozantinib | Other | Phase PHASE3 | Carcinoma, Renal Cell | TERMINATED | NCT04338269 |
| Atezolizumab | Other | Phase PHASE3 | Carcinoma, Renal Cell | TERMINATED | NCT04338269 |
| Pembrolizumab | Other | Phase PHASE2 | Oral Cavity Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07484139 |
| XL092 | Other | Phase PHASE2 | Oral Cavity Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07484139 |
| Pembrolizumab | Other | Phase PHASE2 | Oral Cavity Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07484139 |
| XL092 | Other | Phase PHASE2 | Oral Cavity Squamous Cell Carcinoma | NOT_YET_RECRUITING | NCT07484139 |
| Zanzalintinib | Other | Phase PHASE2 | Neoadjuvant Treatment | RECRUITING | NCT06959511 |
| Zanzalintinib | Other | Phase PHASE2 | Neoadjuvant Treatment | RECRUITING | NCT06959511 |
| Everolimus | Other | Phase PHASE2 | Pancreatic Neuroendocrine Tumor (pNET) | RECRUITING | NCT06943755 |
| Zanzalintinib | Other | Phase PHASE2 | Pancreatic Neuroendocrine Tumor (pNET) | RECRUITING | NCT06943755 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT06545331 |
| XB010 | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT06545331 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | RECRUITING | NCT06863311 |
| XL092 | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | RECRUITING | NCT06863311 |
| Nivolumab | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | RECRUITING | NCT06863311 |
| XL092 | Other | Phase PHASE2 | Advanced Renal Cell Carcinoma | RECRUITING | NCT06863311 |
| Nivolumab | Other | Phase PHASE2 | Locally Advanced Renal Cell Carcinoma | RECRUITING | NCT06794229 |
| Zanzalintinib | Other | Phase PHASE2 | Locally Advanced Renal Cell Carcinoma | RECRUITING | NCT06794229 |
| Nivolumab | Other | Phase PHASE2 | Locally Advanced Renal Cell Carcinoma | RECRUITING | NCT06794229 |
| Zanzalintinib | Other | Phase PHASE2 | Locally Advanced Renal Cell Carcinoma | RECRUITING | NCT06794229 |
| Zanzalintinib | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Yttrium-90 Microsphere Radioembolization | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Tremelimumab | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Single Photon Emission Computed Tomography | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Durvalumab | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Computed Tomography | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Biospecimen Collection | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Biopsy Procedure | Procedure | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Angiogram | Other | Phase PHASE2 | Locally Advanced Hepatocellular Carcinoma | NOT_YET_RECRUITING | NCT07511504 |
| Pembrolizumab | Other | Phase PHASE2 | Phase 2 | SUSPENDED | NCT07283731 |
| Zanzalintinib | Other | Phase PHASE2 | Phase 2 | SUSPENDED | NCT07283731 |
| Tissue biopsy | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | ACTIVE_NOT_RECRUITING | NCT04412629 |
| Blood for plasma biomarkers | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | ACTIVE_NOT_RECRUITING | NCT04412629 |
| Cabozantinib | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | ACTIVE_NOT_RECRUITING | NCT04412629 |
| Tissue biopsy | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | ACTIVE_NOT_RECRUITING | NCT04412629 |
| Blood for plasma biomarkers | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | ACTIVE_NOT_RECRUITING | NCT04412629 |
| Cabozantinib | Other | Phase PHASE2 | High Grade Neuroendocrine Neoplasms | ACTIVE_NOT_RECRUITING | NCT04412629 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT06545331 |
| XB010 | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT06545331 |
| Pembrolizumab | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT06545331 |
| XB010 | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumors | RECRUITING | NCT06545331 |
| Everolimus | Other | Phase PHASE2 | Pancreatic Neuroendocrine Tumor (pNET) | RECRUITING | NCT06943755 |
| Zanzalintinib | Other | Phase PHASE2 | Pancreatic Neuroendocrine Tumor (pNET) | RECRUITING | NCT06943755 |
| Zanzalintinib | Other | Phase PHASE2 | Neoadjuvant Treatment | RECRUITING | NCT06959511 |
Total products: 494